Altimmune
Update in progressALT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Altimmune, Inc. is a late-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 3 trials for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-related liver disease. Founded in 1997, the company is headquartered in Gaithersburg, Maryland.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Jerome Benedict Durso
- Founded1997
- Employees57
- Websitealtimmune.com
Identifiers
- ISINUS02155H2004
- FIGIBBG000FXML90
- LEI549300EOYCQ8SW3NVE64
- CUSIP02155H101
- CIK0001326190